Company
- Company
- Product
- R&D
- Investors
- Culture
History

History

Changes & Advancement Growth & Innovation Start & Take off

Preview

JW Group has started its steps with the restoration of nation’s independence

JW Group’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.

2024
- Commenced Export of Comprehensive Nutritional Infusion 'Winuf' to Mongolia
- Registered Korean Patent for Wnt-targeted Hair Loss Treatment ‘JW0061’
- Signed License-In Agreement with Kissei Pharmaceutical for GnRH Antagonist ‘Linzagolix’
- C&C Research Laboratories, Prostate cancer treatment selected as Korea Drug Development Project
2023
- Completion of relocation to new headquarters in Gwacheon, strengthening 'R&D-focused' management system
- Wnt-targeted hair loss treatment 'JW0061' selected for National New Drug Development Project
- Acquisition of international standard compliance management system 'ISO 37301' certification
- Korean patent registration for sepsis early diagnosis biomarker specific binding antibody
- Launch of Korea's first 'Hybrid Incubator'
2022
- Selection of STAT3-targeted anti-cancer drug 'JW2286' for National New Drug Development Project
- Joint research agreement with Ilias BioLogics
- Joint research agreement with Organoid Science for preclinical translational research
- Joint research agreement with OncoCross for innovative new drug using AI
2021
- Completion of a phase 2b clinical trial of the anti-gout drug URC102
- Enter a phase 2b dose-ranging clinical trial of the new atopic dermatitis drug candidate JW1601
- Signed a non-cxclusive license agreement with Immunovia(Sweden) for the patent 'diagnostic biomarker of pancreatic cancer'
- World's 1st Europeon&Chinese patent registration of diagnostic technique for sepsis
- Signed a license agreement for Fostamatinib with Kissei Pharmaceutical Co.,Ltd.
- The cumulative output of IV product exceed 3 billion
2020
- Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
- Joint development of a next-generation nutrient sap with Baxter
- Conclusion of the Winuf® exclusive technology exportation and provision agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in China
2019
- C&C Research Laboratories, JW Pharmaceutical Subsidiary transfer
- Signed a technology export contract with the Simcere
  company in China,'URC102' for gout treatment
- Acquired 'Euvipharm', the first Vietnamese pharmaceutical
  company in Korea
- Atopic dermatitis ‘JW1601’ won the ‘Technology Exporter’
  and the 'King Sejong the Great', the highest patented
  technology in Korea
- Acquired patents for China and Europe for early diagnosis
  of pancreatic cancer
- A hemophilia drug 'hemri Bra' rare drug designation and
  market sales permit
- Asia’s first sell a three-chamber nutrient infusion in EU
2018
- JW Life Science Industry First "Nutrient Toolking" in Asia Get EU
  – GMP
- Technology export of atopic dermatitis drug 'JW1601'
2017
- 2017 Signed export contract for ‘Ertapenem’,
  the next generation antibiotic with Gland Pharma from India
2016
- JW Lifescience listed on Securities Market
2015
- Vision 70+5 Declaration
2013
- Signed Export Agreement with America’s Baxter for 3-Chamber
  Nourishment Transfusion Fluid
- Joint-Development agreement with Japan’s SKK worth 100 billion
  for pharmaceutical products
- Founded True Medical Personnel respecting life,
  enacted ‘Sungcheon Award’
2012
- Relocation of C&C new medicine research institute
- (DRC hall, Sungkyunkwan University,
  Suwon natural science campus)
2011
- Renamed to JW Holdings Corporation
- Renamed to JW Pharmaceutical Corporation
- Renamed to JW Shinyak Corporation
- Renamed to JW Life Science Corporation
- Renamed to JW Medical Corporation
- Renamed to JW Living Healthcare Corporation
2010
- JW Dangjin Production Complex, which is Korea’s largest
  Medicine-manufacturing plant, was built
2009
- JW Shinyak was listed on the KOSDAQ
- Awarded US$30 mil-Export Tower
2008
- Took over Three-Seven
- Certified as Good Labor Culture Enterprise from Labor Ministry
- Eco-friendly B1 established
2007
- Awarded Presidential Citation on the occasion of Environment Day
- Choongwae Holdings established
2006
- World’s largest Non-PVC supplement plant (Dangjin) was built
2005
- Designated as Korea’s 30-respectable enterprises
- (Dong-A Ilbo Daily, IBM BCS)
- Designated as Asia’s 200 outstanding enterprises (Fobes Asia)
- Choongwae Shinyak established
2004
- Antibiotics, ‘Impenem’ first generic with US$600 mil-scale potential
- Global market developed
- Impenem plant meeting EU GMP standard was built (Sihwa)
2003
- Awarded the 3rd Gyeonggi Green Environment Trophy
  (Gyeonggi Province)
- Awarded the 4th Korea Business Image Grand Prize by KMAC
- Awarded the 5th Industrial Peace Grand Prize
2002
- Awarded New Medicine Development Prize with Balofloxacin
  (Ginko biloba leaf extract)
- Antibiotics Ketoconnazole was certified by Europe COS

Next view

Company

History